IL2 and lymphoma: These findings suggest that the fusion to anti-CD20 antibodies of the mutein IL-2no-alpha that expands preferentially CD8+ T lymphocytes and NK cells over Tregs with less toxicity than IL-2 (25), may be a good effective therapeutic against human lymphomas.